HATRIC-LRC for small molecules
Now available at Dualsystems
Contact form
Please fill out all mandatory (*) fields.
The group of Professor Bernd Wollscheid from ETH Zurich showed in their latest publication that HATRIC-LRC (HATRIC Ligand Receptor Capture) enables the identification of the targets of a small molecule at the cell membrane of living cells to elucidate the mode of action of the molecule. Further, it was demonstrated that the HATRIC-LRC technology platform needs less cells for target identification than the previously published LRC-TriCEPS method and it enables the identification of N-, C-, and O- glycosylated targets.
Target identification using HATRIC-LRC is based on the trifunctional cross linker HATRIC that contains an NHS ester to couple the small molecule, a hydrazone to covalently bind to the carbohydrates of the unknown target proteins at the cell membrane and an azide as pull down function.
The small molecule is coupled to HATRIC using a primary amine. Either your small molecule contains already a primary amine or a primary amine is added by derivatization. In the next step cells expressing the unknown targets and off-targets are mildly oxidized and the HATRIC coupled small molecule is added. The small molecule binds its target(s) at the cell membrane and the second arm of HATRIC covalently binds to the carbohydrates of the target protein(s). During that interaction the cells are still alive. Then the cells are lysed, processed and the third arm of HATRIC is used to pull down the target proteins. Proteins are identified through bottom-up proteomics, relatively quantified and compared to one or several controls. The target candidates are those proteins that are enriched in the ligand of interest samples compared to the control treated samples since the ligand target interaction increases the likelihood of the target carbohydrates to covalently bind to HATRIC compared to the average cell surface protein. Controls can be a positive control such as transferrin or a negative control for example samples treated with an excess of the small molecule devoid of HATRIC prior to adding the HATRIC small molecule conjugate (competition).
Customers Testimonials – LRC-TriCEPS Service
Testimonials from our customers who have used the LRC-TriCEPS technology – in collaboration with Dualsystems Biotech AG.
University of California San Francisco
"We have been trying to identify a receptor that has been sought after for nearly 30 years by laboratories across the globe. Thanks to Dualsystems service CaptiRec (LRC-TriCEPS), we now have a strong candidate receptor." 
De'Broski R. Herbert Ph.D.
Assistant Professor in Residence
University of California San Francisco (UCSF)
De'Broski R. Herbert Ph.D.Assistant Professor in Residence
University of California San Francisco (UCSF)
2015-02-17T14:27:53+00:00
https://www.dualsystems.com/testimonials/captirec-service/
Washington University School of Medicine
"Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems".
Fumihiko Urano, MD, PhD
Samuel E. Schechter Professor of Medicine
Washington University School of Medicine
Fumihiko Urano, MD, PhDSamuel E. Schechter Professor of Medicine
Washington University School of Medicine
2015-02-17T14:30:12+00:00
https://www.dualsystems.com/testimonials/captirec-service-2/
Centro de Estudos de Doenças Crónicas
New publication in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson Gontijo
« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »
Alisson M. Gontijo,
Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas
« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »
Alisson M. Gontijo,Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas
2015-02-24T07:32:40+00:00
https://www.dualsystems.com/testimonials/captirec-service-3/
Igenica Biotherapeutics
«Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»
Dr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics
Dr. Edward van der Horst,Senior Director, Preclinical Development
Igenica Biotherapeutics
2016-05-09T11:13:08+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-4/
East Tennessee State University
“For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.”
Jonathan M Peterson
Assistant Professor
East Tennessee State University
Jonathan M PetersonAssistant Professor
East Tennessee State University
2016-05-30T15:20:03+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service/
Medizinische Hochschule Hannover
“With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.”
Dr. rer. nat. Inga Sörensen-Zender
Postdoc
Medizinische Hochschule Hannover
Dr. rer. nat. Inga Sörensen-ZenderPostdoc
Medizinische Hochschule Hannover
2016-09-26T10:26:51+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-2/
The Rockefeller University
"We are very pleased with the work product of Dualsystems Biotech. The TriCEPS reagent allowed us to identify a novel ligand-extracellular matrix protein receptor interaction, which was not possible using traditional techniques. The Dualsystems team were very helpful in tailoring the experimental conditions to fit our biological question."
Manish Ponda, M.D., M.S.
Assistant Professor of Clinical Investigation
The Rockefeller University
Manish Ponda, M.D., M.S.Assistant Professor of Clinical Investigation
The Rockefeller University
2016-10-10T14:21:51+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-3/
University of Manitoba
"Every aspect of our experience with Dualsystems Biotech was outstanding. They provided excellent customer service and technical support throughout the entire process. Their LRC-TriCEPS technology allowed us to identify several new candidate receptors for our protein of interest in rat primary neurons, and this has created new and exciting avenues for our research."
Sari S. Hannila, PhD
Associate Professor, Department of Human Anatomy and Cell Science
Associate Member, Spinal Cord Research Centre
Max Rady College of Medicine, Rady Faculty of Health Sciences
University of Manitoba
Sari S. Hannila, PhDAssociate Professor, Department of Human Anatomy and Cell Science
Associate Member, Spinal Cord Research Centre
Max Rady College of Medicine, Rady Faculty of Health Sciences
University of Manitoba
2017-06-12T10:05:43+00:00
https://www.dualsystems.com/testimonials/lrc-service/
Münster University Hospital (UKM)
"Dualsystems Biotech’s approach to receptor identification with the TriCEPS reagent gave us a powerful platform with great support for a successful and fast data generation, when conventional approaches had previously failed."
Dr. rer. nat. Martin Herold
Working group from Prof. Dr. med. Luisa Klotz
Münster University Hospital (UKM), Germany
Dr. rer. nat. Martin HeroldWorking group from Prof. Dr. med. Luisa Klotz
Münster University Hospital (UKM), Germany
2017-08-24T14:48:20+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-5/
University of Miami, Miller School of Medicine
We are very pleased with the experience and interaction on very high professional level with Dualsystems Biotech. As a result of such collaboration the new receptor MUC5B was identified in human chondrosarcoma cells for the first time for antiproliferative neuropeptide PRP-1. Read more
I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration.
Dr Karina Galoian
Research associate professor
University of Miami, Miller School of Medicine
Department of Orthopedic surgery
Miami, Florida, USA
I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration.
Dr Karina GaloianResearch associate professor
University of Miami, Miller School of Medicine
Department of Orthopedic surgery
Miami, Florida, USA
2017-11-16T08:07:04+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-6/
QIMR Berghofer Medical Research Institute
“With the help of the team at Dualsystems we confirmed a potential receptor which has lead to a Nature paper submission and successful funding of a research grant. The LRC-TriCEPS experiment was straightforward and the process was cost effective. We look forward to using TriCEPS in the future.”
Anita Burgess | PhD
Hepatic Fibrosis Group
QIMR Berghofer Medical Research Institute, Australia
Anita Burgess | PhDHepatic Fibrosis Group
QIMR Berghofer Medical Research Institute, Australia
2017-12-12T13:21:33+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-7/
Biomedical Research Institute
PUBLICATION: Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J. Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479.
The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics. However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays. We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.
(Quim) Madrenas, MD, PhD, FCAHS
Chief Scientific Officer
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, USA
The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics. However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays. We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.
(Quim) Madrenas, MD, PhD, FCAHSChief Scientific Officer
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, USA
2018-04-19T11:18:18+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-8/
University of Pittsburgh
It was a pleasure working with Paul Helbling and his team. I was impressed by their attention to detail, and optimization of all cell conditions to produce the most reliable possible results. They kept me informed at every stage of the process and shared data as soon as they were able to. Using their LRC-TriCEPS platform, we were able to follow leading candidates as binding partners for our cardiac targeting peptide and identified the most likely binding partner.
Maliha Zahid, M.D., Ph.D.
Assistant Professor
Departement of Developmental Biology
University of Pittsburgh
Maliha Zahid, M.D., Ph.D.
Assistant Professor
Departement of Developmental Biology
University of Pittsburgh
2018-11-15T19:35:14+00:00
https://www.dualsystems.com/testimonials/university-of-pittsburgh/
CuroNZ Ltd
The team from DualSystems Biotech AG has been extremely helpful in delivering scientific advice for CuroNZ’s target identification journey. The quick turnaround time and the precision of NRP2945’s target identification in regard to the utilization of their TRICEPS technology impressed us very much. Meanwhile we could identify another NRP2945 receptor target that was identified by DualSystems as being recruited to the NRP2945-activated membrane receptor complex. An absolute pleasure to work with Paul Helbling’s team.
Frank Sieg, PhD
CSO
CuroNZ Ltd
Mangawhai in New Zealand
Frank Sieg, PhD
CSO
CuroNZ Ltd
Mangawhai in New Zealand
2019-02-20T12:18:04+00:00
https://www.dualsystems.com/testimonials/curonz-ltd/
The University of Oklahoma – Health Sciences Center
I was very pleased with my collaboration with the team at Dualsystems. We had to work with difficult cells and the team helped us develop modifications to the original protocol to be able to use the TriCEPS approach with our cells. The whole team was very responsive, involved, and knowledgeable and this led to a successful identification of a receptor for our ligand of interest. We have since then confirmed the interaction and we are now getting ready to publish this study, which will have implications in the treatment of ocular injuries.
Anne Kasus-Jacobi, PhD
Associate Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA
Anne Kasus-Jacobi, PhD
Associate Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA
2019-07-02T04:38:05+00:00
https://www.dualsystems.com/testimonials/the-university-of-oklahoma-health-sciences-center/
LRC-TriCEPS customers worldwide
Over 200 satisfied customers from 28 countries.
LRC-TriCEPS publications worldwide
LRC-TriCEPS / HATRIC-LRC Publications
Concerning the LRC-TriCEPS or HATRIC-LRC platforms.
